Sobi Acquires Arthrosi Therapeutics for $950M Upfront in Gout Drug Deal

Swedish pharmaceutical company Sobi has agreed to acquire U.S. biotech Arthrosi Therapeutics for $950 million upfront cash (approx. SEK 9.1 billion), with up to $550 million in additional milestone payments, for a total potential value of $1.5 billion.1 2

The deal adds pozdeutinurad (AR882), a next-generation oral URAT1 inhibitor in two fully enrolled Phase 3 trials for progressive and tophaceous gout, with topline results expected in Q2 2026.1 2 3

Transaction funded by new and existing debt facilities, subject to customary conditions, and expected to close in H1 2026.1 2 4

Sobi CEO Guido Oelkers stated the drug could become the therapy of choice for uncontrolled gout and accelerate growth into the mid-2030s.1 3

Arthrosi CEO Litain Yeh highlighted Sobi's commercialization expertise to advance pozdeutinurad.3 4

ApicHope Pharmaceutical retains rights to pozdeutinurad in Greater China.1 4

Sources:

1. https://www.biopharmadive.com/news/sobi-arthrosi-acquire-gout-drug-deal/807849/

2. https://www.prnewswire.com/news-releases/sobi-to-acquire-arthrosi-therapeutics-strengthening-pipeline-for-the-potential-treatment-of-gout-302641735.html

3. https://www.prnewswire.com/news-releases/viva-biotechs-invested-and-incubated-company-arthrosi-has-entered-into-an-acquisition-agreement-with-sobi-for-a-total-transaction-value-of-up-to-us1-5-billion-302641934.html

4. https://www.bioxconomy.com/partnering/sobi-s-950m-acquisition-of-arthrosi-to-expand-gout-pipeline

Sources:

Leave a Reply Cancel reply